Online citations, reference lists, and bibliographies.
← Back to Search

Management And Survival Of Pleural Mesothelioma: A Record Linkage Study

G. Carioli, M. Bonifazi, M. Rossi, A. Zambelli, M. Franchi, C. Zocchetti, S. Gasparini, G. Corrao, C. la Vecchia, E. Negri
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Background: Pleural mesothelioma (PM) is a rare, highly lethal tumor. A definite consensus on its management has yet to be established. Objectives: To assess management, overall survival (OS), and their predictors in a cohort of patients from Lombardy, the largest Italian region (about 10 million inhabitants). Methods: Through a record linkage between Lombardy health care administrative databases, we identified patients diagnosed with PM in 2006–2011 without history of cancer, evaluating their management. OS from PM diagnosis was estimated using the Kaplan-Meier method. Predictors of OS and of treatment were assessed using Cox regression models with time-dependent covariates when appropriate. Results: Out of 1,326 patients, 754 (56.9%) received treatment for PM: 205 (15.5%) underwent surgery, and 696 (52.5%) used chemotherapy. Surgery was spread across several hospitals, and most patients diagnosed in nonspecialized centers (70%) underwent surgery in the same centers. Age at diagnosis was a strong inverse determinant of surgery. Determinants of receiving chemotherapy were younger age, a more recent first diagnosis, and first diagnosis in a specialized center. OS was 45.4% at 1 year, 24.8% at 2 years, and 9.6% at 5 years (median 11 months). OS decreased with age, and was higher for those who underwent surgery, but not for those treated with chemotherapy. Conclusions: Management of PM varied widely in clinical practice, and significant predictors of treatment were younger age and recent diagnosis, though a high proportion of patients were not treated. Patients were treated in various hospitals, indicating the importance of concentrating serious rare neoplasms in Comprehensive Cancer Centers (as recognized by the Italian Health Ministry).
This paper references
10.1097/JOM.0000000000000059
Mesothelioma in Occupational Cohort Studies: Methodological Considerations
Nancy C. Wojcik (2014)
10.3978/j.issn.2072-1439.2014.05.03
Management of malignant pleural mesothelioma-The European experience.
I. Opitz (2014)
10.1136/bmjopen-2014-006029
A validation study of a new classification algorithm to identify rheumatoid arthritis using administrative health databases: case–control and cohort diagnostic accuracy studies. Results from the RECord linkage On Rheumatic Diseases study of the Italian Society for Rheumatology
G. Carrara (2015)
10.1016/0895-4356(92)90133-8
Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases.
R. Deyo (1992)
10.1097/00008469-200006000-00005
An age, period and cohort analysis of pleural cancer mortality in Europe.
C. la Vecchia (2000)
10.1016/j.jss.2015.01.043
Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database.
R. Meyerhoff (2015)
10.1002/ijc.23874
Survival of pleural malignant mesothelioma in Italy: A population‐based study
F. Montanaro (2009)
10.1097/00008469-200006000-00006
An age, period and cohort analysis of pleural cancer mortality in Europe.
U. Suleiman (2000)
10.1016/j.bcp.2016.07.012
New therapeutic strategies for malignant pleural mesothelioma
M. Bonelli (2017)
10.1038/sj.bjc.6690105
The European mesothelioma epidemic
J. Peto (1999)
Lake RA: Malignant mesothelioma
BW Robinson (2005)
10.1016/S1470-2045(11)70307-2
The MARS feasibility trial: conclusions not supported by data.
W. Weder (2011)
10.1002/cam4.824
Updated mortality study of a cohort of asbestos textile workers
E. Pira (2016)
10.1183/09031936.00063109
Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma
A. Scherpereel (2009)
10.1183/16000617.0063-2016
Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment
A. Bibby (2016)
10.1093/AJE/KWM324
Immortal time bias in pharmaco-epidemiology.
S. Suissa (2008)
10.1016/S1470-2045(11)70149-8
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study
T. Treasure (2011)
10.2427/9016
Clinical use, safety and effectiveness of novel high cost anticancer therapies after marketing approval: A record linkage study
E. Negri (2013)
10.1200/JGO.2017.010116
International Analysis of Age-Specific Mortality Rates From Mesothelioma on the Basis of the International Classification of Diseases, 10th Revision
P. Boffetta (2018)
10.1097/JTO.0000000000000064
Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients
P. Bovolato (2014)
Diagnosis related groups: A practitioner's guide
Grimaldi Pl (1982)
10.1097/JTO.0b013e31826915f1
Initial Analysis of the International Association For the Study of Lung Cancer Mesothelioma Database
V. Rusch (2012)
10.2427/8981
Building reliable evidence from real-world data: methods, cautiousness and recommendations
G. Corrao (2013)
10.1634/theoncologist.2011-0184
Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety.
M. Bonifazi (2012)
10.1093/annonc/mdv199
Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
P. Baas (2015)
An international analysis of agespecific mortality rates from mesothelioma based on ICD-10
P Boffetta (2017)
10.1007/BF03320727
Regione Lombardia capo fila nel File F
C. Ragazzo (2009)
10.2427/9036
A new scope and a vision for record linkage studies
G. Corrao (2013)
10.1016/j.lungcan.2015.05.014
Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.
R. Damhuis (2015)
10.5858/arpa.2013-0381-RA
Malignant Mesothelioma Diagnosis.
Qudsia Arif (2015)
10.1007/s10552-016-0838-y
Incidence of malignant mesothelioma in Germany 2009–2013
Martin Lehnert (2016)
10.1016/S1470-2045(17)30169-9
Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial.
E. Alley (2017)
10.1634/THEONCOLOGIST.12-7-850
Multidisciplinary treatment of malignant pleural mesothelioma.
G. Ceresoli (2007)
ADAPTING A CLINICAL COMORBIDITY USE WITH ICD-g-CM ADMINISTRATIVE INDEX FOR DATABASES
R. Deyo (1992)
10.1016/j.jtho.2016.04.028
Consensus Report of the 2015 Weinman International Conference on Mesothelioma
M. Carbone (2016)
10.5858/arpa.2017-0124-RA
Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group.
A. Husain (2018)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar